ScanGrants

Grant Announcements

Updated grant and funding announcements for cardiovascular, diabetes, nutrition, and obesity. Announcements are updated automatically through and RSS feed.
Also check the grants from the Rural Assistance Center for more funding opportunities for nonprofits and individuals.
 
 

Roger R. Williams Memorial Award for Genetic Epidemiology and the Prevention and Treatment of Atherosclerosis

ScanGrants - Cardiovascular -

Roger R. Williams Memorial Award for Genetic Epidemiology and the Prevention and Treatment of Atherosclerosis

Applicants must submit abstracts to the EPI/Lifestyle 2015 Scientific Sessions, scheduled for March 3 -6, 2015 in Baltimore, Maryland.

The Abstract and Award Application Deadline is Wednesday, October 15, 2014 at 11:59 PM CDT.

The Roger R. Williams Memorial Award for Genetic Epidemiology and the Prevention and Treatment of Atherosclerosis is named for Dr. Roger R. Williams' pioneering work in the field of the genetics of inherited lipid disorders and the prevention of atherosclerosis.

The winner of the Roger R. Williams Genetic Epidemiology Award will be announced during the conference. The winning abstract will be the one achieving the highest average score of all applicants who submit abstracts to the category of genetic epidemiology.   The awardee will receive a cash prize of $1,500 and a plaque.

Eligibility Requirements

• All applicants must be members of the American Heart Association (AHA).

• The candidate must be the first and presenting author of the abstract.

• The work may not have been previously presented or published in any form.

• Winners are not eligible to re-enter the competition in subsequent years.

• Applicants may submit only one abstract for consideration for the award.

• Winners of this award are not eligible to receive cash compensation from another award during the joint EPI/Lifestyle Scientific Sessions.

How To Apply

• Submit an abstract for the conference by 11:59 PM CDT on Oct. 15, 2014 to the Genetics category.

• Select the award during the abstract submission process.

• Upload your current curriculum vitae.

This award is made possible by a grant from Merck, Inc.

For questions, please contact:

Susan Kunish
Manager, Scientific Conference Programs
Phone: (720) 328-8078

Trudy Bush Fellowships for Cardiovascular Disease Research in Women's Health

ScanGrants - Cardiovascular -

Trudy Bush Fellowships for Cardiovascular Disease Research in Women's Health

Applicants must submit abstracts to the EPI/Lifestyle 2015 Scientific Sessions, scheduled for March 3 -6, 2015 in Baltimore, Maryland.

The Abstract and Award Application Deadline is Wednesday, October 15, 2014 at 11:59 PM CDT.

The Trudy Bush Fellowship for Cardiovascular Disease Research in Women’s Health is named for Trudy Bush, Ph.D., M.H.S., to honor her outstanding leadership in the field of women’s health and contributions to cardiovascular science.

The winners of the Trudy Bush Fellowships will be announced during the conference.  The winning abstracts will be the top three achieving the highest average scores of all applicants whose abstracts address issues related to women’s health. Cardiovascular disease research in women’s health is defined broadly and is not limited to studies conducted exclusively in women or issues unique to women, such as effects of postmenopausal hormone therapy.  The awardees will receive a cash prize of $1,000 each.

Eligibility Requirements

• All applicants must be members of the American Heart Association (AHA).

• The candidate must be the first and presenting author of the abstract.

• The work may not have been previously presented or published in any form.

• Winners are not eligible to reenter the competition in subsequent years.

• Applicants may submit only one abstract for consideration for the award.

• Winners of this award are not eligible to receive cash compensation from another award during the joint EPI/Lifestyle Scienitific Sessions.

How To Apply

• Submit an abstract for the conference by 11:59 PM CDT, Oct. 15, 2014, in the area of women’s health.

• Select the award during the abstract submission process.

• Upload your curriculum vitae as instructed during the submission process.

For questions, please contact:

Susan Kunish
Manager, Scientific Conference Programs
Phone: (720) 328-8078

Sandra A. Daugherty Award for Excellence in Cardiovascular Disease or Hypertension Epidemiology

ScanGrants - Cardiovascular -

Sandra A. Daugherty Award for Excellence in Cardiovascular Disease or Hypertension Epidemiology

Applicants must submit abstracts to the EPI/Lifestyle 2015 Scientific Sessions, scheduled for March 3 - 6, 2015 in Baltimore, Maryland.

The Abstract and Award Application Deadline is Wednesday, October 15, 2014 at 11:59 PM CDT.

The Sandra A. Daugherty Award for Excellence in Cardiovascular Disease or Hypertension Epidemiology is named for Dr. Sandra Daugherty in appreciation of her outstanding career as a clinical researcher and epidemiologist working in the areas of hypertension, chronic fatigue syndrome and women's health issues. The award is designed to recognize the role of junior faculty and to stimulate excellence in research by junior investigators.

Up to five finalists will be selected by the Council's Program Committee and will be named in the program. The finalists will be asked to submit a five-page manuscript or extended abstract. The winner will be chosen on the basis of his or her contribution to the work as well as the scientific merit, quality and originality of the manuscript submitted. The winner of the Sandra A. Daugherty Award for Excellence in Cardiovascular Disease or Hypertension Epidemiology will be announced during the conference. The awardee will receive a cash prize of $2,500 and a plaque.  The other finalists will be awarded certificates of accomplishment.

Eligibility Requirements

• All applicants and their sponsors must be members of the American Heart Association (AHA).

• Researchers in a junior faculty position, instructor or assistant professor or equivalent, are eligible for this award. Investigators with more than five full-time years of post-training research faculty experience are not eligible.

• The candidate must be the first and presenting author of the abstract.

• The work may not have been previously presented or published in any form.

• Winners are not eligible to reenter the competition in subsequent years.

• Applicants may submit only one abstract for consideration for the award.

• Winners of this award are not eligible to receive cash compensation from another award during the joint EPI/Lifestyle Scienitific Sessions.

How To Apply

• Submit an abstract for the conference by 11:59 PM CDT, Oct. 15, 2014.  The abstract should be based on independent research in the area of cardiovascular disease and/or hypertension.

• Select the award during the abstract submission process.

Upload the following REQUIRED documents as instructed during the submission process:

• Submit a signed letter of endorsement from your department chair, advisor, or other sponsor, certifying that you meet the eligibility criteria for this award.  The letter must describe time spent in training and after completion of training to support your eligibility as a “junior investigator”.

• Submit a current curriculum vitae

• (Finalists will be asked to submit an extended manuscript at a later date).

Supported by a grant from The Sandra A. Daugherty Foundation.

For questions, please contact:

Susan Kunish
Manager, Scientific Conference Programs
Phone: (720) 328-8078

Jeremiah and Rose Stamler Research Award for New Investigators

ScanGrants - Cardiovascular -

Jeremiah and Rose Stamler Research Award for New Investigators

Applicants must submit abstracts to the EPI/Lifestyle 2015 Scientific Sessions, scheduled for March 3 - 6, 2015 in Baltimore, Maryland.

The Abstract and Award Application Deadline is Wednesday, October 15, 2014 at 11:59 PM CDT.

The Jeremiah and Rose Stamler Research Award for New Investigators is named for the Stamlers in appreciation of their seminal contributions to cardiovascular disease epidemiology.  The award recognizes and stimulates excellence in research by investigators in training.

Up to five finalists will be selected by the council’s Program Committee and will be named in the program.  Finalists will be asked to submit a five-page extended abstract, which will be the basis for selecting the recipient of the award.  Finalists are selected based on abstract rating and the winner will be chosen on the basis of his or her contribution to the work as well as scientific merit, quality, and originality of the manuscript submitted.

The winner of the Jeremiah and Rose Stamler award will be announced during the conference.  The awardee will receive a cash prize of $1,000 and a plaque.  The other finalists will be awarded certificates of accomplishment.

Eligibility Requirements

• All applicants and their sponsor(s) must be members of the American Heart Association (AHA).

• Researchers in graduate and postgraduate training programs (degree or non-degree) as well as those in medical residency and fellowship programs are eligible for this award.  Investigators with no more than two years of post-training experience are also eligible.

• The candidate must be the first and presenting author of the abstract.

• The work may not have been presented or published in any form.

• Winners are not eligible to re-enter the competition in subsequent years.

• Applicants may submit only one abstract for consideration for the award.

• Winners of this award are not eligible to receive cash compensation from another award during the joint EPI/Lifestyle Scientific Sessions.

How to Apply

• Submit an abstract to any category for the EPI/Lifestyle Conference by 11:59 PM CDT, Oct. 15, 2015.  The abstract should be based on independent research conducted as part of your training.

• Select the award during the abstract submission process.

Upload the following REQUIRED documents during the submission process:

• Include a signed letter of endorsement from a department chair, advisor or other sponsor, certifying that you meet the eligibility criteria for this award and that the work presented in the abstract is yours.  The letter should include your contribution to the formulation of the research hypothesis, data collection, analysis and interpretation.

• Submit a current Curriculum vitae

• (Finalists will be asked to submit an extended manuscript at a later date).

For questions, please contact:

Susan Kunish
Manager, Scientific Conference Programs
Phone: (720) 328-8078

Prader-Willi Syndrome Association Research Grant Program

ScanGrants - Obesity -

Prader-Willi Syndrome Association Research Grant Program

Prader-Willi Syndrome Association (USA) [“PWSA (USA)”] is pleased to offer grant assistance for scientific researchers with an interest in improving the lives of those with Prader-Willi syndrome (PWS). PWSA(USA) is seeking to fund projects for a maximum of $75,000 total per project for a 1-2 year grant support aimed at discovering and developing treatments, cures and technologies benefiting those with Prader-Willi syndrome.

PWSA(USA) is especially interested in supporting research projects that have the potential for immediate and high impact to the PWS community. The research committee has decided that PWSA(USA) will support research-based translational grants or those showing high promise for translating basic biomedical knowledge to clinical application. The goal is to fast-track better treatment for the syndrome.

While PWSA(USA) is open to insightful grant applications in any subject area, the following areas are of particular interest to our constituency at this time. Research in these areas will receive the highest priority:

PWSA (USA) 2014 Research Priorities

Obesity -- Obesity is the number one threat to the life expectancy and quality of life of someone with PWS. The combination of hyperphagia and slow metabolism can result in extraordinary weight gain which imposes extraordinary stress on both the person with the syndrome and their families. Hyperphagia is the overwhelming problem preventing independent living by anyone with PWS. Controlling the chronic insatiable feeling of hunger and/or extreme drive to eat and increasing the metabolic rate are issues that are the high priorities for PWSA(USA).

Behavioral/psychological issues --Even if weight is controlled, the impact of complex behavioral and psychological issues is significant for the person with PWS and the entire family. Potential behavioral health interventions are a high priority for PWSA(USA).

Respiratory and Gastrointestinal (GI) complications -- Due to lifelong hypotonia and complications of obesity, individuals with PWS are at-risk for pulmonary and severe gastrointestinal issues. These can be potentially life-threatening and PWSA(USA) believes of high priority.

Other complications --There are other health related complications that are unique to PWS and are potentially life-threatening.

Grant Award Timing:

GRANT APPLICATION DUE: OCT 7, 2014

GRANT AWARD: DEC 2014

FUNDING OF GRANT: As soon as all IRB documents are obtained and completed as well as meeting other requirements.

Request for Proposals: Promising Program Grant Program

ScanGrants - Nutrition -

Request for Proposals: Promising Program Grant Program

NB3F Promising Program Grant cycle is currently open and proposals will be accepted until Monday, July 14, 2014 at 5:00 p.m. (MST)

The Notah Begay III Foundation (NB3F)’s national program, Native Strong: Healthy Kids, Healthy Futures is pleased to announce its 2014 Promising Program Grant Request For Proposals (RFP). NB3F’s mission is to reduce childhood obesity and type 2 diabetes and support leadership development for Native American children through the development of evidence-based health and wellness programs, strategic grantmaking, research and advocacy.

Currently, 45 percent of Native American children ages 6-11 are either overweight or obese. In some Native
communities, childhood obesity rates are over 60 percent with some children as young as four years of age
contracting type 2 diabetes. Unfortunately, there is a shortage of funding resources and support, both public
and private, for Native communities to effectively and adequately address this issue. NB3F believes that Native communities have the inherent knowledge, assets and values to address this health issue within their communities.

Promising Program Grants were designed to assist Native communities in the implementation of culturally
appropriate childhood obesity prevention programming by providing resources and technical assistance.

The purpose of the Native Strong: Healthy Kids, Healthy Futures Promising Program Grant
is to:

1. Strengthen existing programs focused on childhood obesity and type 2 diabetes prevention through physical activity and/or healthy nutrition;

2. Assist communities and organizations in building their capacity to evaluate their programming and;

3. Assist communities and organizations in building their capacity to implement policy change.

Recipients of these grants are currently implementing programs for youth that increase physical activity and get kids moving while providing a safe place to play and/or support healthy nutrition programs that can include nutrition education and/or increasing access to healthy and affordable foods.

The Promising Program Grant will give priority to proposals that show strong potential to strengthen their
existing program, readiness to build their capacity to evaluate their programs and demonstrate strong potential to share promising outcomes and best practices.

NB3F plans to award grants of up to $40,000 each to support projects that strategically target childhood obesity and type 2 diabetes prevention through physical activity and/or healthy nutrition programs.

Examples of proposed work could be but are not limited to:

• Nutrition education and child/youth engagement through community gardens (i.e. farm to school
programming)

• Child/Youth engagement through organized sports programs

• Child/Youth focused community physical activity (i.e. walking trails, outdoor activities)

• Child/Youth leadership development through nutrition education and physical fitness programming

Policy Change:

In addition to strengthening areas of program implementation and building capacity to conduct
program evaluation, this grant is targeted at identifying policy interventions to combat childhood obesity and type 2 diabetes. Policy change can be large, like adapting a tribal youth fitness policy or smaller scale such as offering healthy snack options at meetings/events or creating “junk food free zones” at program sites.

As a requirement of this grant, each grantee must develop at least one policy intervention that will be addressed during the grant period.

Moreover, technical assistance will be provided to assist in this area of targeted change.

Grant Period

The grant period will commence September 1, 2014 – August 31, 2015.

Eligibility Criteria

Organizations eligible to apply include U.S. based Native American-controlled nonprofits 501(c)(3), federally or state recognized tribal governments or programs, or Native American community-based groups with a 501(c)(3) fiscal sponsor. Schools are not eligible to apply unless they have 501(c)(3) status.

Applications will be accepted from throughout the U.S. However, preference will be given to applicants located in the following areas: New Mexico, Arizona (Southwest Region); Oklahoma, Texas (Southern Plains Region); Wisconsin, Minnesota (Upper Midwest Region).

Funding Priorities and Requirements

• Organizations must directly engage children and youth (ages 5-17) in ongoing programming that involves
physical activity and/or healthy nutrition;

• Programs must be at least one year old as of the application opening date (June 2, 2014);

• Programs must be able to demonstrate impact and a commitment to provide continuous and ongoing
programing throughout the grant period.

• Be able to demonstrate evidence of strong tribal leadership and community support; Organizations must
provide a letter of support from the Native community where the program will be operating.

• Have experience in and the capacity to build sustainable programming in the core areas of physical
activity and/or healthy nutrition;

• Demonstrate ability to enhance existing programming and capacity to strengthen existing evaluation
efforts;

• Have strong organizational capacity to implement the proposed project and manage the grant funds,
including prohibitions against lobbying and political activities;

• Demonstrate ability to provide a 30 percent match of the total project request (cash and/or in-kind);

• Demonstrate indirect costs do not exceed 15% of the total project request;

• Demonstrate a “balanced” budget according to organizational needs (for example no requests for
equipment only, salaries only, etc.;
 

Request for Proposals: Promising Program Grant Program

ScanGrants - Obesity -

Request for Proposals: Promising Program Grant Program

NB3F Promising Program Grant cycle is currently open and proposals will be accepted until Monday, July 14, 2014 at 5:00 p.m. (MST)

The Notah Begay III Foundation (NB3F)’s national program, Native Strong: Healthy Kids, Healthy Futures is pleased to announce its 2014 Promising Program Grant Request For Proposals (RFP). NB3F’s mission is to reduce childhood obesity and type 2 diabetes and support leadership development for Native American children through the development of evidence-based health and wellness programs, strategic grantmaking, research and advocacy.

Currently, 45 percent of Native American children ages 6-11 are either overweight or obese. In some Native
communities, childhood obesity rates are over 60 percent with some children as young as four years of age
contracting type 2 diabetes. Unfortunately, there is a shortage of funding resources and support, both public
and private, for Native communities to effectively and adequately address this issue. NB3F believes that Native communities have the inherent knowledge, assets and values to address this health issue within their communities.

Promising Program Grants were designed to assist Native communities in the implementation of culturally
appropriate childhood obesity prevention programming by providing resources and technical assistance.

The purpose of the Native Strong: Healthy Kids, Healthy Futures Promising Program Grant
is to:

1. Strengthen existing programs focused on childhood obesity and type 2 diabetes prevention through physical activity and/or healthy nutrition;

2. Assist communities and organizations in building their capacity to evaluate their programming and;

3. Assist communities and organizations in building their capacity to implement policy change.

Recipients of these grants are currently implementing programs for youth that increase physical activity and get kids moving while providing a safe place to play and/or support healthy nutrition programs that can include nutrition education and/or increasing access to healthy and affordable foods.

The Promising Program Grant will give priority to proposals that show strong potential to strengthen their
existing program, readiness to build their capacity to evaluate their programs and demonstrate strong potential to share promising outcomes and best practices.

NB3F plans to award grants of up to $40,000 each to support projects that strategically target childhood obesity and type 2 diabetes prevention through physical activity and/or healthy nutrition programs.

Examples of proposed work could be but are not limited to:

• Nutrition education and child/youth engagement through community gardens (i.e. farm to school
programming)

• Child/Youth engagement through organized sports programs

• Child/Youth focused community physical activity (i.e. walking trails, outdoor activities)

• Child/Youth leadership development through nutrition education and physical fitness programming

Policy Change:

In addition to strengthening areas of program implementation and building capacity to conduct
program evaluation, this grant is targeted at identifying policy interventions to combat childhood obesity and type 2 diabetes. Policy change can be large, like adapting a tribal youth fitness policy or smaller scale such as offering healthy snack options at meetings/events or creating “junk food free zones” at program sites.

As a requirement of this grant, each grantee must develop at least one policy intervention that will be addressed during the grant period.

Moreover, technical assistance will be provided to assist in this area of targeted change.

Grant Period

The grant period will commence September 1, 2014 – August 31, 2015.

Eligibility Criteria

Organizations eligible to apply include U.S. based Native American-controlled nonprofits 501(c)(3), federally or state recognized tribal governments or programs, or Native American community-based groups with a 501(c)(3) fiscal sponsor. Schools are not eligible to apply unless they have 501(c)(3) status.

Applications will be accepted from throughout the U.S. However, preference will be given to applicants located in the following areas: New Mexico, Arizona (Southwest Region); Oklahoma, Texas (Southern Plains Region); Wisconsin, Minnesota (Upper Midwest Region).

Funding Priorities and Requirements

• Organizations must directly engage children and youth (ages 5-17) in ongoing programming that involves
physical activity and/or healthy nutrition;

• Programs must be at least one year old as of the application opening date (June 2, 2014);

• Programs must be able to demonstrate impact and a commitment to provide continuous and ongoing
programing throughout the grant period.

• Be able to demonstrate evidence of strong tribal leadership and community support; Organizations must
provide a letter of support from the Native community where the program will be operating.

• Have experience in and the capacity to build sustainable programming in the core areas of physical
activity and/or healthy nutrition;

• Demonstrate ability to enhance existing programming and capacity to strengthen existing evaluation
efforts;

• Have strong organizational capacity to implement the proposed project and manage the grant funds,
including prohibitions against lobbying and political activities;

• Demonstrate ability to provide a 30 percent match of the total project request (cash and/or in-kind);

• Demonstrate indirect costs do not exceed 15% of the total project request;

• Demonstrate a “balanced” budget according to organizational needs (for example no requests for
equipment only, salaries only, etc.;
 

Interstitial Cystitis Association Pilot Research Program

ScanGrants - Nutrition -

Interstitial Cystitis Association Pilot Research Program

Help us solve the many questions that surround IC!

The Interstitial Cystitis Association (ICA) Pilot Research Grant is a one-year award of $25,000 intended to fund novel and useful basic, clinical, or translational research studies that attempt to solve the many questions of interstitial cystitis (IC). Specific areas of interest are (but not limited to):

Deadline to apply is February 27, 2015

■ Epidemiology/burden of disease (especially in children)

■ Etiology of IC

■ Serum or urine markers

■ Treatment modalities

■ Neurophysiology

■ Pain management

■ Pregnancy and IC

■ Diet and nutrition

The award period is June 1, 2015 through May 31, 2016.

ELIGIBILITY

In order to be eligible for this award, the applicant must adhere to the following guidelines:

1. Applicant should have a sponsoring institution.

2. Applicant must be able to complete the proposed project within one year.

3. Applicant does not hold other research awards for the same or for a similar project.

AWARD DETAILS AND REQUIREMENTS

Awardee(s) will be granted an award of up to $25,000 over one year provided in two equal installments of $12,500. The first installment will be provided to the awardee(s) at the start of the award period (June 1). Funding of the second installment is contingent upon final approval by the ICA Research Committee of both a six-month progress report and final report that must be submitted within 30 days of the conclusion of the award period (May 31, 2016). A final report will not be accepted for any project for which a six month progress report was not approved. The ICA Research Committee must approve any requests for extensions of the reporting/funding period.

The number of awards granted will depend on the amount of funding available and the caliber of proposed projects. The amount of money awarded ultimately depends on the scope and budget of each individual study.

The use of award funds is restricted to research based on the purposes and methodology outlined in the application. No funds may be used toward administrative overhead costs.

Recipients must acknowledge the award in all publications resulting from research performed during the tenure of this award. Abstracts, manuscripts, or other articles that reflect research funded by this award must acknowledge support from ICA and copies must be forwarded to ICA.

The award cannot be transferred to another person at the sponsoring institution. Permission for a transfer of sponsoring institution must be authorized by ICA in advance of the event or the award will be terminated on the date the awardee ceases to work at the sponsoring institution to which the award was initially remitted.

SELECTION CRITERIA

Candidates will be evaluated based on their background, their commitment to research, the impact their research project will make in the IC community, and the environment in which they will conduct this project.

The ICA Research Committee, made up of members of the ICA Medical Advisory Board, will review the applications and select award recipients. Applications will be reviewed based only on the written materials submitted. All decisions are final. Incomplete applications and applications that fail to adhere strictly to the instructions (including the submission deadline and page limitations) will not be reviewed. Selection decisions will be announced in April 2015.

DEADLINE

The application deadline for this award is 11:59 PM Eastern time on February 27, 2015. The completed application and other documents as applicable must be combined into and submitted as one PDF document. The document must be titled by the applicant's last name and first initial only. Hard copies are not permitted. Please email the application to research@ichelp.org with “ICA Pilot Research Program Grant Application” in the subject line.

If you have any further questions, please contact ICA at research@ichelp.org. The deadline to apply is February 27, 2015.

Weight Watchers Karen Miller-Kovach Research Grant

ScanGrants - Obesity -

Weight Watchers Karen Miller-Kovach Research Grant

Weight Watchers and TOS have partnered to create the Karen Miller-Kovach Research Grant, which will award a research grant of $40,000 for a one-year period. The grant will focus on the development of a scalable, behavioral weight management program that includes digital tools.

Eligibility Criteria

All members of the Obesity Society (domestic or international) are eligible for the grant.

Post-doctoral students and above.

Post-doctoral research fellows must be current members in their own right and have a mentor who is a current TOS member.

Applications should be submitted to TOS by Monday, June 30, 2014 at 11:59 am ET.

Applicants whose LOI are judged well will be announced on July 31, 2014 and will be invited to submit a Proposal of no more than 4 pages (plus one page for budget and justification, plus biosketch pages) by August 29, 2014.

Important dates

Letter of Intent Submission Deadline: June 30, 2014

Full Proposal Request Notification: July 31, 2014

Full Proposal Submission Deadline: August 29, 2014

Grant Recipient Notified: September 30, 2014

Grant Start Date: Approximately November 1, 2014

Research Completed: One year from Start Date November 1, 2015

Final Report and Financial Statement Due: One year from Start Date November 1, 2015

For more information

For additional details regarding this grant, please contact Jean McMahon via email at grantsandawards@obesity.org or at 240-485-1955 by phone.

Requests for Applications: American Diabetes Association and Boehringer Ingelheim Research Award: Chronic Kidney Disease and Renal Insufficiency in the Setting of Diabetes

ScanGrants - Diabetes -

Requests for Applications: American Diabetes Association and Boehringer Ingelheim Research Award: Chronic Kidney Disease and Renal Insufficiency in the Setting of Diabetes

Deadline: September 15, 2014

This award is designed to support basic, clinical or translational research to better understand the issues surrounding the relationship between diabetes and chronic kidney disease (CKD). Specifically, these grants would support research aimed at 1) understanding the mechanisms underlying the development of renal complications in people with diabetes, and 2) improving the treatment and management of people with chronic kidney disease and diabetes.

Support

Basic science projects will receive a maximum of $345,000 over three years ($115,000 per year, including indirect costs). Clinical or translational science projects will receive a maximum of $660,000 over three years ($220,000 per year, including indirect costs). Indirect costs cannot exceed 15% of requested direct costs; if subcontracts are used, any associated indirect costs must be incorporated into the 15% yearly maximum.
 

Request for Letters of Intent: Glucose Responsive Insulin Discovery and Validation

ScanGrants - Diabetes -

Request for Letters of Intent: Glucose Responsive Insulin Discovery and Validation

Letter of Interest Deadline: July 11, 2014

JDRF, the world’s leading non-profit organization with the mission to cure, treat and prevent type 1 diabetes
(T1D), invites Letters of Intent (LOI) for the discovery and validation of novel glucose responsive insulin
(GRI) drugs for better treatment of insulin-dependent diabetes mellitus (IDDM) and reducing the burden of daily management of the disease, particularly T1D.

Proposals (supported by strong rationale and/or preliminary data) will be considered for a maximum
budget of up to $500,000* per year for up to 3 years of funding (including 10% indirect costs)

* Applications whose budget and/or timeline exceeds the above specified guidelines, must
obtain JDRF staff approval prior to submitting an LOI

OBJECTIVES

Letters of intent are sought from academic or industry applicants with innovative approaches to discover and
provide validation (proof-of-concept) for insulin delivery proportional to circulating real time levels of blood glucose in animal models of T1D.

Early concepts with limited preliminary results may be considered at reduced scope, budget and timelines
based on strength of hypothesis and feasibility of approach.

Designing glucose-responsive insulins may require a concerted effort from various areas of expertise.
Therefore, applications from a network of investigators and/or collaborations leveraging expertise in protein biochemistry, pharmacology, drug delivery, formulation sciences, bioengineering and other fields, as applicable, will be given a high priority.

Alternately, JDRF Staff may suggest collaborations between two or more applicants based upon complementarity to form a network.

Expected outcomes from project proposals would demonstrate but be not limited to:

-- Insulin release and blood glucose lowering proportional to circulating levels of glucose

-- Improvements in glycemic parameters–glucose tolerance, reduced hypoglycemia, etc.

-- Reversibility of mechanism

-- Safety and tolerability of biomaterials, excipients, etc.

-- Pharmacokinetic and pharmacodynamic measures

-- Evidence of elimination of biomaterials, if any

Applications should contain an analysis of the projected GRI product concept compared to standard-of-
care, including:

-- Target Product Profile and Target Patient Profile

-- Reduced frequency of dosing (such as once-a-day)

-- Reduced need for monitoring blood glucose levels

-- Reduced risk for hypo and hyperglycemia

-- Timelines for development

-- Cost/benefit analysis

-- Competitive landscape

Applicants are encouraged to consult with JDRF Scientific Staff to discuss the alignment of their proposal to this RFA and in developing the projected GRI product concept

Collaborations with industry and/or direct applications by companies are strongly encouraged.

Request for Expressions of Interest: Exploratory Clinical Trials of Non-insulin Adjunct Therapies in Type 1 Diabetes

ScanGrants - Diabetes -

Request for Expressions of Interest: Exploratory Clinical Trials of Non-insulin Adjunct Therapies in Type 1 Diabetes

Expression of Interest Deadline: July 11, 2014

JDRF, the world’s leading non-profit organization with the mission to cure, treat and prevent type 1 diabetes (T1D), invites Expressions of Interest (EOI) for clinical trials to evaluate non-insulin based adjunct therapies for improved glycemic and overall metabolic control of T1D.

JDRF has an unprecedented opportunity to make progress in the clinical assessment of adjunctive therapies for T1D that move beyond an insulin-centric view of the disease.

At present, several agents–mostly approved T2D therapies such as incretins, SGLT inhibitors, metformin–
are under clinical investigation to assess the benefit: risk profile in T1D. However, a systematic clinical phenotyping of the heterogeneous disease to enable personalized interventions addressing specific dysfunctional pathways or an understanding of the mechanistic pathology is yet to be undertaken. It is our goal to de-convolute the T1D disease complexity such that sub-groups of individuals can be identified and stratified to determine optimal therapeutic regimen of non-insulin adjunct therapies, thus maximizing the benefit: risk ratio for the patients.

JDRF wishes to solicit expressions of interest for clinical trials in established from academic and industry
applicants T1D to test the safety, efficacy, and potential synergies of adjunct therapies that target multiple facets of the disease.

Request for Letters of Intent: Exploratory Clinical Trials for Diabetic Retinopathy

ScanGrants - Diabetes -

Request for Letters of Intent: Exploratory Clinical Trials for Diabetic Retinopathy

LOI Submission Deadline: .June 20th 2014

JDRF is committed to facilitating the translation of therapies for diabetic retinopathy to individuals with Type 1 Diabetes (T1D). To this end, JDRF is soliciting letters of intent for clinical trials of novel therapies for non-proliferative (NPDR), or proliferative retinopathy (PDR).

Diabetic retinopathy is a sight-threatening complication of diabetes and the largest cause of blindness in the US. Despite recent advances in the treatment of diabetic macular edema, there remains a large unmet clinical need to prevent or reverse vision loss via the treatment of NPDR and PDR.

OBJECTIVES

Letters of intent are sought from investigators with for innovative approaches to arrest or reverse NPDR or
to resolve PDR.

Exploratory and initial proof of concept clinical trials which could provide a strong scientific rationale for larger or pivotal studies will be given highest priority.

Clinical trials must include subjects with T1D; however trials will be considered which also propose enrollment of those with Type 2 Diabetes (T2D). Proof of concept clinical studies may propose use of approved or investigational products based on an excellent scientific rationale. JDRF is particularly interested in clinical trials which propose novel means of subject stratification based on estimated risk of progression of NPDR.

Endpoints of interest include: Change in ETDRS scale; prevention of progress ion or improvement

Visual acuity

Other well-justified measures of visual function

Progression to proliferative diabetic retinopathy

Vision-related quality of life scores

Clinical trials of up to 36 months duration will be considered. Investigators proposing trials exceeding this duration should contact Dr Helen Nickerson to assess whether submission is possible.

Under exceptional circumstances, proposals which also include preclinical studies may be considered if needed to obtain regulatory approval to move forward with the proposed clinical trial. Please contact Dr Helen Nickerson to discuss studies in this area.

Request for Expressions of Interest: Clinical Trials to Preserve Beta Cell Function and Delay Onset of Symptomatic Disease in the At-risk Setting for Type 1 Diabetes (T1D)

ScanGrants - Diabetes -

Request for Expressions of Interest: Clinical Trials to Preserve Beta Cell Function and Delay Onset of Symptomatic Disease in the At-risk Setting for Type 1 Diabetes (T1D)

Expression of Interest deadline: July 11, 2014

JDRF is soliciting expressions of interest (EOI) for performing secondary prevention clinical trials to preserve beta cell function and delay the onset of symptomatic disease.

These EOIs may include proof-of-concept clinical trials with existing and/or novel therapies and with combination therapies that target different aspects of beta cell dysfunction and loss.

Objectives

Expressions of interest are sought from investigators with access to patient cohorts of individuals with ≥2
T1D autoantibodies to conduct proof-of-concept clinical trials using intermediate trial outcomes/endpoints
to inform larger and longer prevention trials. Intermediate endpoints to be considered include: increasing
HbA1c, onset of dysglycemia, reversal of dysglycemia, change in C-peptide, etc.). Repurposed and/or
novel therapeutics (immune, inflammation, beta cell survival, metabolic, etc.) will be considered.
Combination therapies, used either sequentially or simultaneously, for robust prevention will also be
considered.

Investigators with ideas or resources that might benefit this initiative should also submit their ideas via an
expression of interest.

Mechanistic studies should be built into all trials.

JDRF is concurrently releasing an EOI for Combination Therapies in Type 1 Diabetes.

This EOI is not meant as a replication of that EOI, which focuses on combination therapies for new-onset and established T1D.

Furthermore, EOIs with a focus on primary prevention will not be considered

Mechanism

EOIs in response to this announcement can be submitted to the following mechanism:

Clinical Strategic Research Agreements (supported by strong preliminary data) for a maximum budget of
$1,500,000* per year for up to 3 years of funding (including 10% indirect costs)

Pre-clinical support may be requested only for IND-enabling activities.

* Applications whose budget and/or timeline exceeds the above specified guidelines, must obtain JDRF
staff approval prior to submitting an LOI.

Applications that are not funded in this competition may be resubmitted to other JDRF grant mechanisms
according to the deadlines and guidelines described on the JDRF Web site:
http://www.jdrf.org/

Request for Applications: Identifying and Prioritizing Drug Targets and Combination Therapies to Simultaneously Optimize Regenerative and Survival Responses in the Beta Cell

ScanGrants - Diabetes -

Request for Applications: Identifying and Prioritizing Drug Targets and Combination Therapies to Simultaneously Optimize Regenerative and Survival Responses in the Beta Cell

Letter of Intent Deadline: July 17, 2014

JDRF invites applications from single investigators or teams of investigators to develop and conduct studies to identify and prioritize pathways, mechanisms, combination approaches and therapies to safely promote human beta cell regeneration while maintaining beta cell survival and function.

This RFA will support performance-driven, milestone-based pre-clinical research programs aimed at identifying and validating drug targets and biologic factors to simultaneously promote human beta cell regeneration and prevent beta cell loss.

It is expected that RFA-sponsored studies may ultimately have implications for treatment of type 1 diabetes and that the data generated may be used to support longer-term drug discovery efforts. Inclusion of studies with human islets/beta cells will be prioritized.

Up to a maximum of $250,000 USD per year including 10% indirect costs for up to 2 years may be requested.

The level of funding will vary depending on the scope and over all objectives of the proposal.

Proposals with significantly higher cost may still be considered at the discretion of JDRF scientists.

Request for Applications: Targeting Islet Cell Plasticity for Regeneration of Beta Cell Function in T1D

ScanGrants - Diabetes -

Request for Applications: Targeting Islet Cell Plasticity for Regeneration of Beta Cell Function in T1D

Letter of Intent Deadline: July 17, 2014

JDRF invites applications from single investigators or teams of investigators to develop and conduct studies
to identify and prioritize pathways, mechanisms, factors and drug targets to guide therapeutic approaches to drive formation of new beta cells by targeting islet cell plasticity.

This RFA will support performance-driven, milestone-based research programs aimed at identifying and validating mechanisms, pathways and potential drug targets regulating islet cell plasticity.

It is expected that the RFA-sponsored studies may ultimately have implications for treatment of type 1 diabetes and that the data generated may be used to support longer-term efforts aimed at drug discovery and translation.

Proposals that include studies on human islets will be prioritized.

Up to a maximum of $250,000 USD per year including 10% indirect costs for up to 2 years may be requested.

The level of funding will vary depending on the scope and overall objectives of the proposal.

Proposals with significantly higher cost may still be considered at the discretion of JDRF scientists.

Request for Applications: JDRF Encapsulation Consortium: Developing and Testing Novel Encapsulation Technologies

ScanGrants - Diabetes -

Request for Applications: JDRF Encapsulation Consortium: Developing and Testing Novel Encapsulation Technologies

Full applications should be submitted no later than August 1, 2014 at 5 p.m. EST via RMS360 (http://jdrf.smartsimple.us).

One of JDRF’s therapeutic goals is to restore beta cell function in type 1 diabetes (T1D) by replacement/transplantation of beta cells/islets.

Pancreatic islet transplantation has been efficacious in selected patients in improving metabolic control and quality of life, and in preventing severe hypoglycemia in patients with medically unstable T1D. Despite improvements in cadaveric pancreas procurement, islet isolation, and islet purification, major scientific and technical challenges remain that must be addressed before beta cell replacement will be widely incorporated into the clinical management of established T1D; examples include serious side effects from chronic immunosuppression, islet sensitivity to certain immunosuppressants, the insufficient human islet supply from cadaveric pancreata, and the desire for an alternative transplantation site. JDRF’s role is to enable the scientific community to address these challenges with the ultimate goal of developing safe and effective transplantation approaches available to large numbers of individuals with T1D.

Each project may request up to total $350,000 USD per year (including 10 % indirect costs), for up to three years.

Innovative pilot and feasibility studies without significant preliminary data may request up to total $150,000
USD per year for one year (including 10 % indirect costs).

Indirect costs may not exceed 10% of the direct costs.

Applicants are strongly advised to consult with the JDRF Programmatic Contact by July 1, 2014 to discuss the responsiveness of their proposal to this program. 

Call for Nominations: American Diabetes Association Richard R. Rubin Award

ScanGrants - Diabetes -

Call for Nominations: American Diabetes Association Richard R. Rubin Award

Formerly the Behavioral Medicine & Psychology Interest Group Lectureship for Distinguished Contributions, the Richard R. Rubin Award Lecture is given in memory of Richard R. Rubin, PhD, CDE, a long time Association volunteer, who served as President, Health Care and Education, and chair of the Council on Behavioral Medicine & Psychology, and received numerous professional and service awards. Specifically, the Richard R. Rubin Award recognizes a behavioral researcher who has made outstanding and/or innovations contributions in the study and understanding of the behavioral aspects of diabetes.

Criteria for Selection: Principal criteria for selection: To recognize a behavioral researcher who has made outstanding and/or innovative contributions in the study and understanding of behavioral aspects of diabetes. Nominee will be recognized for national and/or international contributions to the field of behavioral medicine in diabetes Nominee must be an active American Diabetes Association member. No specific degree requirements, but a clinical/research focus in behavioral health is strongly preferred Both U.S. and non-U.S. residents are eligible for Award. Contributions as an American Diabetes Association volunteer and to the broader diabetes community may also be taken into consideration.

Lecture/Publication of Lecture: Recipient will deliver the Richard R. Rubin Award Lecture at the 75th Scientific Sessions in Boston, Massachusetts; June 5-9, 2015. Offered the opportunity to publish lecture in an American Diabetes Association scientific journal.

Honorarium/Travel/Registration: The recipient receives a $1,000 honorarium. Award includes complimentary hotel accommodations for up to 3-nights within an Association hotel block and one round-trip coach airfare. Includes one complimentary registration to Scientific Sessions.

2015 Nomination/Submission Process: 2015 Nominations must be submitted using the new electronic nomination form. All submissions must be received on or before 8pm ET, July 25, 2014. Nominations are accepted from any professional member of the American Diabetes Association. Nominations from the membership of the Behavioral Medicine & Psychology Interest Group in particular are encouraged and will be solicited.

All Richard R. Rubin Award nominations must have the following documents uploaded as one .pdf file:

-- Letter of nomination (no more than 400 words), signed by no more than 3 individuals, will be accepted. Letter of nomination should address criteria for selection.

-- Nominee’s biography

-- Please include nominee’s CV with career and publication highlights, as well as documentation of teaching and mentorship must also be included.

Questions? Contact Mary Merkin, Senior Manager, Scientific and Medical by email at mmerkin@diabetes.org or call 703-549-1500, ext 1371.

Selection: The recipient is chosen by a selection committee comprised of the Chair of the Behavioral Medicine and Psychology Section and the past 3 recipients of the Award. The selection committee will review and discuss all nominations and select the recipient on the basis of outstanding achievement or innovative contributions that have led to advances in the study and understanding of behavioral aspects of living with diabetes and its prevention and treatment. The selection process is reviewed and supported by the National Medicine, Science and Health Care Awards Committee. The nominee is approved by the Executive Committee of the American Diabetes Association.

Call for Nominations: American Diabetes Association Roger E. Pecoraro Award

ScanGrants - Diabetes -

Call for Nominations: American Diabetes Association Roger E. Pecoraro Award

Given in memory of Roger E. Pecoraro, MD, a pioneer in research on the causes and prevention of foot ulcers and amputations in diabetes, The Roger E. Pecoraro Lectureship Award recognizes a researcher who has made scientific contributions and demonstrates an untiring commitment to improving the understanding of detection, treatment and prevention of diabetic foot complications.

Criteria for Selection: Principal criteria for selection: recognizing significant and/or innovating scientific achievement in improving the understanding of detection, treatment and prevention of diabetic foot complications Nominee will be recognized for national and/or international contributions to the field of research on diabetes complications Nominee must be an active American Diabetes Association member. Impact as a teacher and mentor will also be taken into consideration. Eligible candidates hold an doctorate level clinical or research degree (MD, DO, DPM, PhD) Both US and non-US residents are eligible Contributions as an American Diabetes Association volunteer and to the broader diabetes community may also be taken into consideration.

Lecture/Publication of Lecture: Recipient will deliver the Roger Pecoraro Award Lecture at the 75th Scientific Sessions in Boston, Massachusetts; June 5-9, 2015. Offered the opportunity to publish lecture in an American Diabetes Association scientific journal.

Honorarium/Travel/Registration: The recipient receives a $1,000 honorarium. Award includes complimentary hotel accommodations for up to 3-nights within an Association hotel block and one round-trip coach airfare. Includes one complimentary registration to Scientific Sessions.

2015 Nomination/Submission Process: 2015 Nominations must be submitted using the new electronic nomination form. All submissions must be received on or before 8pm ET, July 25, 2014. Nominations are accepted from any professional member of the American Diabetes Association. Nominations from the membership of the Interest Group in Foot Care are encouraged and will be solicited.

All Roger Pecoraro Award nominations must have the following documents uploaded as one .pdf file:

-- Letter of nomination (no more than 400 words), signed by no more than 3 individuals, will be accepted. Letter of nomination should address criteria for selection.

-- Nominee’s biography

-- Please include nominee’s CV with career and publication highlights, as well as documentation of teaching and mentorship must also be included.

Questions? Contact Mary Merkin, Senior Manager, Scientific and Medical by email at mmerkin@diabetes.org or call 703-549-1500, ext 1371.

Selection: Nominations are reviewed and scored by selected experts and past chairs from the Council on Foot Care appointed by the current chair of the Interest Group on Foot Care. The selection process is reviewed and supported by the National Medicine, Science and Health Care Awards Committee. The nominee is approved by the Executive Committee of the American Diabetes Association.

Pages

Subscribe to PlantBasedResearch.org aggregator - ScanGrants